{
    "clinical_study": {
        "@rank": "48782", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the abuse liability and examine the reinforcing\n      effects of intravenous buprenorphine and buprenorphine/naloxone combinations in\n      buprenorphine-naloxone maintained volunteers"
        }, 
        "brief_title": "Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4", 
        "completion_date": {
            "#text": "August 1999", 
            "@type": "Actual"
        }, 
        "condition": [
            "Heroin Dependence", 
            "Opioid-Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heroin Dependence", 
                "Opioid-Related Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ongoing study - results not available at this time"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA\n        criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence\n        disorders may also be present. Individuals must be healthy despite drug dependency and\n        have a history of IV opioid use.\n\n        Exclusion Criteria:\n\n        Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental\n        Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,\n        organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular\n        disease) or pregnant female subjects are excluded from study participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000329", 
            "org_study_id": "NIDA-11160-4", 
            "secondary_id": [
                "R01DA011160", 
                "R01-11160-4"
            ]
        }, 
        "intervention": {
            "intervention_name": "Opioid-Related Disorders", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80206"
                }, 
                "name": "University of Colorado Health Sciences Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Leslie Amass, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 1999", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Subjective dose estimate"
            }, 
            {
                "measure": "Observed withdrawal rating"
            }, 
            {
                "measure": "Opioid agonist rating"
            }, 
            {
                "measure": "Opioid antagonist rating"
            }, 
            {
                "measure": "Pupil diameter"
            }, 
            {
                "measure": "Analog rating scale for drug effects"
            }, 
            {
                "measure": "Drug effect characteristics"
            }, 
            {
                "measure": "Drug/Money Preferences"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 1999", 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }, 
    "geocoordinates": {
        "University of Colorado Health Sciences Center": "39.739 -104.985"
    }
}